Trial Profile
Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Mar 2019
Price :
$35
*
At a glance
- Drugs Cetrorelix (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Therapeutic Use
- 01 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
- 01 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2017.
- 07 Dec 2016 Planned End Date changed from 1 Oct 2016 to 1 Mar 2017.